
    
      This is a 500 subject Multi Center double-blind randomized, Safety & Efficacy, HIV/AIDS Phase
      III study, to primarily to evaluate the safety and efficacy of HIV-1 immunogen & Amplivax
      compared to placebo group Amplivax in viral load, and secondarily to examine changes in CD4+
      & CD8+ T cell counts, determine Remune vaccines effect of multiple inoculations of HIV-1
      immunogen + Amplivax on viral replication in adults with HIV-1 infection & to examine
      immunogenicity of Remune + Amplivax in a Multi-center, randomized , double-blind,
      placebo-controlled, two arm parallel design study of Remune + Amplivax.
    
  